Courier Health Raises $50M to Keep More Specialty Therapy Patients on Their Medications

"The life sciences industry continues to generate breakthrough specialty therapies, but the patient support infrastructure connecting those medicines to the people who need them has not kept pace. Siloed data, manual processes, and disconnected systems leave biopharma commercial teams operating without a unified view of the patient journey - a problem so acute that roughly 30% of patients who receive a specialty drug prescription never start that therapy, and 70% discontinue within the first few months."

"Courier Health addresses this gap directly with the only purpose-built patient experience platform for life sciences commercial teams, connecting disparate data sources, applying AI to proactively surface at-risk patients, and coordinating the full journey from prescription through long-term adherence. Companies using the platform have recorded gains exceeding 15% in patient start rates, a 67% reduction in time-to-start, and seven-fold increases in team productivity - outcomes that translate directly to patients accessing therapies they depend on."

"Tell us about the product or service that Courier Health offers. Courier Health provides the only purpose-built techn"

"We raised a $50M Series B led by Oak HC/FT, with participation from our existing investors Norwest and Work-Bench. We're thrilled to partner with Oak HC/FT, a team that has a deep appreciation for what it takes to build lasting infrastructure and impact in healthcare, and we're grateful to continue our partnership with Irem Rami from Norwest and Jess Lin from Work-Bench."

The life sciences industry produces specialty therapies, but patient support systems have not kept pace. Siloed data, manual workflows, and disconnected systems prevent biopharma commercial teams from seeing the full patient journey. About 30% of patients who receive a specialty drug prescription never start therapy, and 70% discontinue within the first few months. Courier Health provides a purpose-built patient experience platform for life sciences commercial teams. The platform connects disparate data sources, uses AI to proactively identify at-risk patients, and coordinates the journey from prescription through long-term adherence. Reported results include more than 15% gains in patient start rates, a 67% reduction in time-to-start, and seven-fold increases in team productivity. The company expanded therapy coverage and headcount in 2025 to meet demand, and raised a $50M Series B led by Oak HC/FT.

Read at AlleyWatch